GIGABYTE-TECHNOLOGY
Renowned globally for its research and development capabilities, GIGABYTE Technology will exhibit its products and solutions at COMPUTEX from June 4 to June 7 under the theme "ACCEVOLUTION," acclaiming the new era of accelerated-computing and time of AI. AI remains a major trend, attracting industry leaders, including the highest number of CEOs in COMPUTEX history. In celebration, Taipei 101 will be illuminated for COMPUTEX, with GIGABYTE lighting it up on June 4 from 6:30 PM to 10:00 PM, promoting the AI event and welcoming international guests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602653282/en/
Shining Bright atop Taipei 101, GIGABYTE Redefines AI Evolution Accelerated by Next-Generation Computing at COMPUTEX (Photo: Business Wire)
Prominent leaders in global chip development will attend COMPUTEX, aiming to assert their influence in the AI era and strengthen ties with the Taiwanese supply chain. GIGABYTE, an integral part of this industry, is honored to invite these CEOs to its booth to explore the latest technologies. GIGABYTE's diverse product lineup spans the entire AI lifecycle, featuring industry-leading technologies and flexible server solutions. These products, designed to meet future computing demands with advanced cooling solutions, will be showcased on an unprecedented scale at COMPUTEX. Additionally, GIGABYTE will present its Red Dot Award-winning PC products, new products demos, and AI experiences for gamers and creators.
GIGABYTE has consistently been the fastest to market with the most diverse range of AI servers. This year, the G593 flagship AI server series, known for its high-density features and flexible design, is displayed to support NVIDIA's next-gen chips H200 and B100, as well as models designed for AMD's MI300X. The showcase will also feature the new X series servers, based on NVIDIA's MGX modular design, which shortens development times and accelerates data center deployment. Customers can choose between AMD EPYC, Intel Xeon x86 CPUs, or NVIDIA Grace Hopper Arm superchips, offering tailored configurations for specific computational needs.
Large Language Models (LLM) have become increasingly popular in AI. To handle the growing number of parameters, GIGABYTE is showcasing servers supporting NVIDIA's latest Blackwell architecture, featuring the highly acclaimed high-density designs with the powerful B100 and B200 superchips. The B100 will be compatible with the G593 series hardware, while the B200's next-level performance introduces thermal challenges beyond the capacity of traditional air cooling. GIGABYTE has addressed this with its industry-leading thermal engineering by employing direct liquid cooling. The highly anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as the GB200 NVL72, acting as a massive GPU that can achieve 30 times the inference performance of an equivalent number of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions about the future of AI development and computing deployment.
Introducing GIGA POD, GIGABYTE’s one-stop rack integration solution leveraging its 20+ years of server proficiency and experience gained from CSP partnerships. GIGA POD is a complete system integration including architecture planning, equipment integration, software installation, and post-deployment testing. It offers different configurations of AI servers with NVIDIA SXM or AMD Instinct GPUs or NVIDIA Superchips and is gradually expanding to future top-tier GPU-equipped AI servers. GIGA POD is also a prime demonstration of GIGABYTE’s thermal engineering, fitting an HGX module in a 5U chassis of an air-cooled G593 server. Such dense server enables customers the option to choose either a 9-rack configuration with 4 AI servers per 42U rack or a 5-rack configuration with 8 AI servers per 48U rack, achieving nearly double the utilization space and greatly improving resource efficiency. GIGABYTE has also invited Northern Data Group, a key client of its cluster computing solution (GIGA POD) and Europe’s largest generative AI cloud service provider, to participate in a special event "Executive Dialogue with AI Visionaries" with the General Manager of GIGABYTE's subsidiary, Giga Computing. The live conversation will cover the collaboration, keys to success, and perspectives on the future of AI.
AI development extends beyond GPU computations to comprehensive data center infrastructure, including storage and network transmission. GIGABYTE's R&D expertise in thermal, mechanical, and modular design ensures a diverse product range across IT architectures. At COMPUTEX, GIGABYTE will showcase servers for cloud and edge computing, high-performance, and high-density storage. Additionally, general-purpose servers for SMBs and DIY server motherboards for micro-enterprises and individuals will be displayed, supporting AI development at all scales.
GIGABYTE has pioneered advanced cooling solutions, mastering technologies like direct liquid and immersion cooling. With expertise in cross-disciplinary integration, GIGABYTE has developed its own cold plates, DLC racks, and immersion tanks, offering comprehensive cooling solutions. At COMPUTEX, GIGABYTE will showcase single-phase immersion cooling, direct liquid cooling, and a new rear-door heat exchanger (RDHx) cooling rack. Collaborating with nVent, GIGABYTE deployed Spain's third-ranked supercomputer, Hyperion, using full-rack servers with RDHx. This setup, connected to an outdoor chiller, delivers up to 54,000 watts of heat dissipation per hour, reducing air conditioning needs and effectively managing computational hotspots.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
The rise of AI is transforming personal computing. GIGABYTE's Z790 series motherboards are designed for different scenarios, and support RTX 40 SUPER series graphics cards, deliver peak performance with enhanced core counts, VRAM, and memory speeds. Utilizing AI acceleration, the graphics cards offer exceptional computing and graphics processing for both professional tasks and AAA gaming, while preparing users for new AI-driven applications. The AORUS 17X and 16X AI laptops feature GIGABYTE's AI Nexus with AI Boost, AI Generator, and AI Power Gear, providing improved performance, seamless AI generation, and extended battery life. At our booth's AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602653282/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
